Fig. 3: Predicting disease progression by baseline pFN as assessed by first milestone-free survival analysis.

a, b first milestone-free survival curves for the discovery cohort (a) and validation cohort (b), stratified into low-pFN and high-pFN groups according to an optimal cutoff point of 197.6 mg/L. pFN plasma fibronectin.